Results 131 to 140 of about 97,685,983 (158)

Cellular Consequences, Citrullination Substrates, and Antigenicity of Targeting PAD4 to Cell Surfaces. [PDF]

open access: yesACS Cent Sci
Kong S   +5 more
europepmc   +1 more source

Pathogenicity of <i>P. gingivalis</i> strains carrying clusters of specific polymorphic variants of peptidylarginine deiminase gene. [PDF]

open access: yesFront Cell Infect Microbiol
Strzelec K   +17 more
europepmc   +1 more source
Some of the next articles are maybe not open access.

Related searches:

Polymorphism of protein tyrosine phosphatase non‐receptor type 22 and protein arginine deiminase 4 gene among Ghanaian rheumatoid arthritis patients: A case–control study

International Journal of Rheumatic Diseases, 2022
AbstractAimRheumatoid arthritis (RA) is an autoimmune disease which affects millions of lives globally characterized by chronic inflammation in the joints of the body. There is no known cause for RA; however, genetic predisposition has been associated with its occurrence.
Samuel Asamoah Sakyi   +7 more
openaire   +2 more sources

Synthesis and Biological Evaluation of an Indazole-Based Selective Protein Arginine Deiminase 4 (PAD4) Inhibitor [PDF]

open access: yesACS Medicinal Chemistry Letters, 2018
Protein arginine deiminase 4 (PAD4) is a calcium-dependent enzyme that catalyzes the conversion of arginine to citrulline within target proteins. Dysregulation of PAD4 has been implicated in a number of human diseases, including rheumatoid arthritis and ...
Jonathan A. Ellman   +2 more
exaly   +2 more sources

Novel Furan-Containing Peptide-Based Inhibitors of Protein Arginine Deiminase Type IV (PAD4) [PDF]

open access: yesChemical Biology and Drug Design, 2017
Protein arginine deiminase type IV (PAD4) is responsible for the posttranslational conversion of peptidylarginine to peptidylcitrulline. Citrullinated protein is the autoantigen in rheumatoid arthritis, and therefore, PAD4 is currently a promising ...
Bimo Ario Tejo   +2 more
exaly   +2 more sources

Enhanced antibacterial activity of a novel protein-arginine deiminase type-4 (PADI4) inhibitor after conjugation with a biocompatible nanocarrier

Journal of Drug Delivery Science and Technology, 2022
Moupiya Ghosh   +6 more
openaire   +1 more source

Home - About - Disclaimer - Privacy